Saturday 17 October 2026
Export CYTOF’s income statement to Excel — free account
Altamira Therapeutics Ltd.
CYTOF Healthcare Biotechnology
Altamira Therapeutics Ltd.’s revenue for fiscal 2022 (year ended December 2022) was $320,300.00.
0.09
0.00
0.00%
Follow CYTOF
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Altman Z-Score |
— | — | — | (60.32) | (13.99) | — | — | — | — | — |
P/S ratio |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | (144.21) | (34.77) | — | — | — | — | — |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
P/Operating CF |
— | — | — | (0.10) | (0.71) | — | — | — | — | — |
P/B ratio |
— | — | — | 0.03 | 0.10 | — | — | — | — | — |
Price to Tangible BV |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
EV/Sales |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
— | — | — | (0.39) | (0.26) | — | — | — | — | — |
EV/FCF |
— | — | — | (0.32) | (0.21) | — | — | — | — | — |
Quick Ratio |
0.02 | 1.16 | 1.06 | 0.08 | 0.40 | 3.74 | 0.85 | 1.25 | 1.46 | 3.65 |
Current Ratio |
0.06 | 1.32 | 1.38 | 0.14 | 0.77 | 3.83 | 1.04 | 1.33 | 1.52 | 3.76 |
Net Debt/EBITDA |
(0.27) | 0.15 | 0.16 | (0.21) | 0.05 | 2.04 | 0.22 | 0.36 | 0.20 | 0.67 |
Debt/Assets |
14.41% | 0.00% | 0.00% | 93.13% | 0.61% | 2.52% | 0.00% | 14.53% | 56.81% | 34.67% |
Debt/Equity |
0.38 | 0.00 | 0.00 | (0.71) | 0.01 | 0.03 | 0.00 | 0.39 | (4.68) | 0.87 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.68 | 0.72 | 2.98 | 0.33 | 0.79 | 0.59 | 1.27 | 1.15 | 0.99 | 0.96 |
Capex/Depreciation |
0.21 | (0.81) | 0.00 | (18.02) | (43.58) | (115.39) | (98.01) | (25.08) | (1.25) | (2.50) |
Interest Coverage |
(29.04) | (8.19) | (3.55) | (28.66) | (90.16) | (39.08) | (253.69) | (10.24) | (14.85) | (36.48) |
| (61.66%) | (118.79%) | 829.81% | (1,071.90%) | (119.71%) | (73.00%) | (136.13%) | (1,532.55%) | (407.96%) | (105.24%) | |
| (35.73%) | (95.05%) | (54.69%) | (204.28%) | (88.92%) | (55.58%) | (68.87%) | (83.32%) | (91.34%) | (69.89%) | |
ROIC |
(66.25%) | (76.92%) | (61.90%) | 0.00% | (90.30%) | (54.71%) | (102.37%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
72.76% | (1,776.08%) | (1,084.16%) | 238.76% | 1,580.02% | (94.98%) | (4,082.57%) | (748.37%) | (428.63%) | (122.15%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 910.51 | 5,367.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 6,437.81% | 13,991.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,971.46% | 10,087.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.58 | 0.53 | 0.51 | 0.62 | 0.76 | 0.44 | 0.73 | 0.36 | 0.09 | 0.04 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 112.14% | 1,888.13% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
— | — | — | (44.58) | (1.79) | — | — | — | — | — |
Graham Number |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
— | — | — | (52.90%) | (7.86%) | — | — | — | — | — |
Free Cash Flow Yield |
— | — | — | (14,438.75%) | (1,668.79%) | — | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 7.04 | 2.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.37) | (2.16) | (26.09) | (199.98) | (451.94) | (344.40) | (1,157.26) | (6,764.30) | (49,343.00) | (74,760.75) |
Capex per Share |
0.01 | (0.04) | 0.00 | (49.35) | (109.94) | (164.63) | (416.19) | (931.90) | (311.00) | (620.25) |
Free Cash Flow per Share |
(0.37) | (2.20) | (26.09) | (249.33) | (561.88) | (509.03) | (1,573.45) | (7,696.20) | (49,654.00) | (75,381.00) |
Cash per Share |
0.00 | 0.35 | 2.09 | 6.58 | 32.53 | 800.58 | 221.21 | 2,757.00 | 30,434.80 | 82,346.50 |
Shareholders Equity per Share |
0.57 | 2.32 | 15.63 | (191.50) | 419.94 | 1,192.45 | 832.25 | 1,865.70 | (4,395.00) | 35,898.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 |
Book value per Share |
0.57 | 2.32 | 15.63 | (191.50) | 419.94 | 1,192.45 | 832.25 | 1,865.70 | (4,395.00) | 35,898.00 |
Free Cash Flow |
(1.97) | (6.22) | (12.81) | (11.34) | (18.60) | (7.64) | (11.49) | (15.39) | (24.83) | (30.15) |
Working Capital |
(4.17) | 0.38 | 0.40 | (11.64) | (1.20) | 9.16 | 0.10 | 1.54 | 5.53 | 25.11 |
Capital Expenditures |
0.03 | (0.10) | — | (2.25) | (3.64) | (2.47) | (3.04) | (1.86) | (0.16) | (0.25) |
Net Current Asset Value |
(4.64) | (0.55) | (0.01) | (13.46) | (2.60) | 8.09 | (0.82) | (0.17) | (4.19) | 12.36 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | — | 7.01 | 52.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.75 | 1.27 | 0.00 | 0.00 | 0.00 | 0.43 | 0.46 | 2.14 | 0.49 | 0.26 |
Cash ROIC |
(47.00%) | (82.19%) | (147.22%) | 501.33% | (123.15%) | (25.07%) | (149.36%) | (143.68%) | (106.50%) | (50.38%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.35 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.33 | 1.01 | 0.02 | 0.02 | 0.14 | 0.08 | 0.06 |
Inventory Turnover |
— | — | — | 3.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 1,242.35 | 602.38 | 13,935.12 | 11,118.37 | 3,062.05 | 3,572.14 | 6,873.12 |
Days of Inventory on Hand |
— | — | — | 2.94 | 136.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.21 | 0.22 | 0.44 | 0.91 | 0.56 | 0.21 | 0.33 | 0.29 | 0.27 | 0.48 |
Average Payables |
1.25 | 0.54 | 2.84 | 4.60 | 2.43 | 0.88 | 1.41 | 1.55 | 1.54 | 1.54 |
Average Inventory |
— | — | — | 0.47 | — | — | — | — | — | — |
Average Assets |
8.30 | 8.90 | 7.87 | 13.61 | 21.40 | 15.74 | 9.69 | 14.11 | 27.16 | 44.54 |
Average Common Equity |
4.81 | 7.12 | (0.52) | 2.59 | 15.89 | 11.98 | 4.90 | 0.77 | 6.08 | 29.58 |
Columns are period end dates · fundamentals updated 14 Oct 2026